|
Inventiva S.A. (IVA): Marketing Mix [Jan-2025 Updated] |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
Inventiva S.A. (IVA) Bundle
In the dynamic world of biotechnology, Inventiva S.A. (IVA) emerges as a pioneering force, transforming the landscape of pharmaceutical innovation with its cutting-edge approach to treating complex fibrotic diseases and cancer. By leveraging advanced small molecule therapies and a strategic global development strategy, this French-based company is poised to revolutionize medical treatments, offering hope to patients through its groundbreaking research pipeline and lead drug candidate, Lanifibranor for non-alcoholic steatohepatitis (NASH). Dive into the intricate marketing mix that drives Inventiva's mission to redefine therapeutic possibilities in the biotechnology sector.
Inventiva S.A. (IVA) - Marketing Mix: Product
Biotechnology Pharmaceutical Company Profile
Inventiva S.A. is a clinical-stage biotechnology pharmaceutical company specializing in developing innovative small molecule therapies.
Therapeutic Focus Areas
| Disease Area | Primary Focus |
|---|---|
| Fibrotic Diseases | Targeted therapeutic interventions |
| Oncology | Cancer treatment development |
Lead Drug Candidate: Lanifibranor
Lanifibranor is the company's primary drug candidate targeting non-alcoholic steatohepatitis (NASH).
- Phase 3 clinical trial status for NASH treatment
- Potential first-in-class therapeutic approach
- Targets peroxisome proliferator-activated receptors (PPARs)
Research Pipeline
| Therapeutic Program | Development Stage |
|---|---|
| NASH Treatment | Phase 3 clinical trials |
| Oncology Programs | Preclinical and clinical stages |
Scientific Capabilities
- Advanced medicinal chemistry expertise
- Proprietary drug discovery platform
- Innovative small molecule design
Product Development Strengths
Key technological capabilities include:
- Sophisticated molecular screening techniques
- Targeted therapeutic approach
- Comprehensive research infrastructure
Inventiva S.A. (IVA) - Marketing Mix: Place
Headquarters and Physical Location
Inventiva S.A. is headquartered at Parc Eurasanté, 940 Avenue Eugène Avinée, 59120 Loos, France, with primary research and development facilities located in Daix, France.
Geographic Market Distribution
| Market Region | Focus Level | Key Activities |
|---|---|---|
| European Market | Primary | Clinical development, research partnerships |
| North American Market | Secondary | Drug commercialization targeting |
Distribution Channels
- Direct pharmaceutical partnerships
- Clinical research collaborations
- International licensing agreements
- Academic and research institution networks
Research and Development Facilities
Primary Location: Daix, France Total Research Space: Approximately 2,500 square meters of specialized laboratory facilities
International Partnerships
| Partner Type | Number of Active Partnerships | Geographic Spread |
|---|---|---|
| Pharmaceutical Companies | 3-4 active collaborations | Europe and North America |
| Research Institutions | 5-6 ongoing research collaborations | International academic networks |
Market Expansion Strategy
- Focus on European pharmaceutical markets
- Strategic expansion into North American clinical development
- Targeted drug commercialization approach
Inventiva S.A. (IVA) - Marketing Mix: Promotion
Scientific Conferences and Medical Symposium Presentations
| Conference Type | Frequency | Target Audience |
|---|---|---|
| International Medical Conferences | 3-4 per year | Hepatology and Fibrosis Specialists |
| European Rare Disease Conferences | 2 per year | Research Physicians |
Investor Relations Through Financial Roadshows and Conference Calls
Quarterly earnings conference calls conducted with average participation of 45-50 institutional investors.
| Investor Communication Method | Frequency | Reach |
|---|---|---|
| Quarterly Earnings Calls | 4 times annually | 50+ institutional investors |
| Annual Investor Day | 1 time per year | 100+ financial analysts |
Peer-Reviewed Publications Highlighting Clinical Research
- Average of 6-8 peer-reviewed publications annually
- Targeted journals in hepatology and rare disease research
- Cumulative citation index of 45-50 in past three years
Digital Communication Channels
| Digital Platform | Followers/Subscribers | Post Frequency |
|---|---|---|
| Corporate Website | 15,000+ monthly visitors | Weekly updates |
| 3,500+ followers | 2-3 posts per week | |
| 2,100+ followers | 1-2 posts per week |
Targeted Communication with Healthcare Professionals
Direct Communication Metrics:
- Quarterly medical education webinars: 250-300 participants
- Personalized clinical research updates: Sent to 1,200+ specialists
- Annual medical advisory board meetings: 15-20 key opinion leaders
Inventiva S.A. (IVA) - Marketing Mix: Price
Pre-revenue Biotechnology Company Status
Inventiva S.A. is classified as a pre-revenue biotechnology company with no current product sales. As of 2024, the company's financial strategy focuses on research and development investments.
Funding Mechanisms
| Funding Source | Amount (EUR) | Year |
|---|---|---|
| Venture Capital Funding | €35.7 million | 2023 |
| Public Offering | €22.5 million | 2022 |
| Research Grants | €4.2 million | 2023 |
Market Valuation Factors
- Clinical development progress for lanifibranor in NASH
- Ongoing research in fibrotic diseases
- Potential therapeutic pipeline value
Cost Management Strategy
Research and Clinical Trial Investment Breakdown:
| Investment Category | Expenditure (EUR) | Percentage of Budget |
|---|---|---|
| Clinical Trials | €18.3 million | 45% |
| Research and Development | €14.6 million | 36% |
| Administrative Costs | €7.1 million | 19% |
Pricing Approach
Current pricing strategy is focused on potential future therapeutic value of drug candidates, particularly lanifibranor for NASH treatment.
Financial Performance Indicators
- Net Cash Position: €42.1 million (Q4 2023)
- Cash Burn Rate: Approximately €5.2 million per quarter
- Expected Cash Runway: Until Q3 2025
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.